ArticleFrontiers in oncology2025
Clinical efficacy of hepatic arterial infusion chemotherapy combined with transhepatic arterial embolization plus lenvatinib and tislelizumab or transarterial chemoembolization combined with lenvatinib plus tislelizumab in the treatment of advanced hepatocellular carcinoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Transarterial infusion chemotherapy combined with lenvatinib and tislelizumab versus intravenous chemotherapy for unresectable pancreatic ductal adenocarcinoma: a retrospective propensity score matching analysis.Frontiers in oncology · 2026Article
- MRI-based clinical-radiomics-habitat model for predicting prognosis of hepatocellular carcinoma patients treated with HAIC.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Advanced hepatocellular carcinoma (HCC) remains a challenge for clinical treatment. The purpose of this study is to compare the efficacy of a quadruple combination of hepatic arterial infusion chemotherapy (HAIC) with transhepatic arterial embolization (TAE), lenvatinib, and tislelizumab (THLP group) with that of a triple combination of transarterial chemoembolization (TACE) with lenvatinib and tislelizumab (TLP group) in advanced HCC. Methods: In this retrospective study, we analyzed clinical information on patients diagnosed with advanced HCC with different treatments between October 2020 and December 2022 at Wuming Hospital. Primary outcomes included overall survival (OS), and progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR). Results: The study included 116 patients, 69 in the TLP group and 47 in the THLP group. Median OS and PFS for the entire cohort were 13 (95% CI, 12.0-14.0) and 9.0 (95% CI, 7.7-10.2) months. OS (median, 17 vs. 12 months, Conclusion: The quadruple combination of HAIC, TAE, lenvatinib, and tislelizumab in the treatment of advanced HCC has a better prognosis than the triple combination of TACE in combination with lenvatinib and tislelizumab, with tolerant safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.